Actively Recruiting
Safety and Effectiveness Study of Olverembatinib Combined with APG-2575 in Children with Relapsed or Refractory Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-08-26
19
Participants Needed
4
Research Sites
47 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, effectiveness, and how the body processes olverembatinib, a third-generation tyrosine kinase inhibitor, combined with APG-2575 in children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia Ph ALL. This phase 1b open-label study aims to find the best dosing for these medications in children who have not responded well to previous treatments or have specific mutations. Participants will undergo a 6-week treatment starting after screening. The first 2 weeks involve taking olverembatinib alone, followed by 4 weeks of combination therapy with olverembatinib, APG-2575, and dexamethasone. Depending on their leukemia remission status after 2, 4, and 6 weeks, patients will either continue maintenance therapy with these drugs or switch to other anti-cancer treatments. Doses may be adjusted based on any side effects experienced, following specific guidelines. During the study, participants will be closely monitored for safety and treatment response. This includes assessing dose-limiting toxicities, measuring drug levels in the blood, and evaluating leukemia remission rates over 42 to 132 days. Laboratory tests, physical exams, and performance status assessments will help guide treatment adjustments and evaluate outcomes. The study is expected to continue until 2027, with ongoing safety and efficacy evaluations throughout.
CONDITIONS
Brief Title
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
Research Team
J
Jingliao Zhang, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here